JPRN-jRCT2031220095已完成2 期
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects
Kanmuri Kazuhiro0 个研究点目标入组 102 人开始时间: 2022年5月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 102
研究概览
简要总结
Obicetrapib 2.5 mg; 5 mg and 10 mg markedly and significantly reduced LDL-C, ApoB, and non HDL C, and increased HDL-C compared to baseline and placebo; -The LDL-C values using PUC were similar to the LDL-C values calculated using a hybrid of the Friedewald equation and PUC; -The PK profile for obicetrapib showed near complete elimination of obicetrapib by 4 weeks after daily dosing; -The study drug was well tolerated, with no evidence of any safety signals related to obicetrapib therapy.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1. Understanding of the study procedures, willingness to adhere to the study schedules, and agreement to participate in the study by giving written informed consent prior to screening procedures;
- •2. Japanese men or women, 18 to 80 years of age, inclusive, at the Screening Visit;
- •o Women may be enrolled if all 3 of the following criteria are met:
- •- They are not pregnant;
- •- They are not breastfeeding; and
- •- They do not plan on becoming pregnant during the study.
- •o Women of childbearing potential must have a negative urine pregnancy test at the Screening Visit. Note: Women are not considered to be of childbearing potential if they meet 1 of the following criteria as documented by the Investigator:
- •- They have had a hysterectomy or tubal ligation at a minimum of 1 cycle prior to signing the ICF; or
- •- They are postmenopausal, defined as >=1 year since their last menstrual period for women >=55 years of age or >=1 year since their last menstrual period and have a follicle-stimulating hormone (FSH) level in the postmenopausal range for women <55 years of age.
- •o Women of childbearing potential must agree to complete abstinence or to use an effective method of avoiding pregnancy from screening to 90 days after the last visit. Men whose partners are of childbearing potential must agree to complete abstinence or to have the partner use an effective method of avoiding pregnancy from screening to 90 days after the last visit. Effective methods of avoiding pregnancy are contraceptive methods with a Pearl index of <1 (oral contraceptives or intrauterine devices) used consistently and correctly o a sterile sexual partner;
- •3. Patients that have not achieved treatment goals in accordance with the 2022 Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases and have documented LDL-C > 70 mg/dL or non-HDL-C >100 mg/dL, and TG < 400 mg/dL, within the last 3 months. If a historical LDL-C or non-HDL-C, and TG values are not available within the last 3 months, a fasting lipid profile to verify eligibility will be required by the central laboratory at the Screening Visit.
- •4. Currently receiving stable statin therapy with either atorvastatin 10 or 20 mg/day or rosuvastatin 5 or 10 mg/day ONLY for at least 8 weeks prior to screening with the intention of remaining on the same stable dose throughout the study duration.
- •o Patients on stable statin therapy with either atorvastatin or rosuvastatin AND taking concomitant daily oral ezetimibe as a second line agent are also eligible to participate.
排除标准
- •1. Body mass index >=35 kg/m2 at the Screening Visit;
- •2. Current clinically active/acute episode of CV disease, including but not limited to:
- •o Major adverse CV event within 3 months prior to randomization, including:
- •- Non-fatal myocardial infarction;
- •- Non-fatal stroke;
- •- Hospitalization for heart failure; or
- •- Hospitalization for unstable angina.
- •o New York Heart Association Functional Classification Class III or IV heart failure.
- •3. Have an existing diagnosis of homozygous familial hypercholesterolemia;
- •4. Have an existing diagnosis of CETP deficiency;
- •5. Glycosylated hemoglobin (HbA1c) >=10% at the Screening Visit;
- •6. Uncontrolled hypertension, i.e., supine systolic blood pressure >=160 mmHg and/or supine diastolic blood pressure >=100 mmHg, taken as the average of triplicate measurements. One retest will be allowed, at which point if the retest result is no longer exclusionary, the participant may be randomized;
- •7. Active muscle disease or persistent creatine kinase (CK) concentration >3 x the upper limit of
- •normal (ULN). One retest will be allowed after 1 week to verify the result, at which point if the retest result is no longer exclusionary, the participant may be randomized;
- •8. Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2, calculated using the Chronic Kidney Disease Epidemiology Collaboration equation;
- •9. Hepatic dysfunction as evidenced by any laboratory abnormality as follows: gamma-glutamyl transferase, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) >2 x ULN, or total bilirubin >1.5 x ULN;
- •10. Anemia, defined as hemoglobin concentration <11 g/dL for men and hemoglobin concentration <9 g/dL for women;
- •11. History of malignancy within 5 years prior to screening, with the exception of non-melanoma skin cancers;
- •12. History of alcohol and/or drug abuse within 5 years prior to screening;
- •13. Treatment with a statin that is not either atorvastatin or rosuvastatin;
- •14. Treatment with other investigational products or devices within 30 days or 5 half-lives, whichever is longer, prior to screening;
- •15. Treatment with any PCSK9 inhibitor within 10 weeks prior to randomization or bempedoic acid within 2 weeks prior to randomization;
- •16. Evidence of any other clinically significant, non-cardiac disease or condition that, in the opinion of the Investigator, would preclude participant in the study; or
- •17. Known CETP inhibitor allergy or intolerance.
研究者
相似试验
已完成
3 期
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and TaiwanHypercholesterolemiaNCT02289963Sanofi199
已完成
3 期
Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)HypercholesterolemiaNCT02023879Sanofi233
已完成
3 期
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)HypercholesterolemiaNCT02107898Sanofi216
已完成
3 期
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of StatinHypercholesterolemiaNCT02584504Sanofi163
进行中（未招募）
1 期
A Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in patients withHeterozygous Familial Hypercholesterolemia (HeFH) and/or Atherosclerotic Cardiovascular Disease (ASCVD, the narrowing of arteries from a buildup of plaque) whose current treatment with lipid-modifying therapies is not sufficiently effective.dyslipidemiaheterozygous familial hypercholesterolemia (HeFH)atherosclerotic cardiovascular disease (ASCVD)MedDRA version: 20.1Level: LLTClassification code 10020049Term: High cholesterolSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.0Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 26.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0Level: LLTClassification code 10076622Term: Atherosclerotic plaqueSystem Organ Class: 10047065 - Vascular disordersEUCTR2021-005065-40-DKewAmsterdam Pharma B.V.2,400